SecBot SecBot
8-K ·Filed Aug 10, 2026

APGE

Apogee Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0001193125-26-341239
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

With the $135.11/share all-cash acquisition by AbbVie pending close in Q3 2026, APGE shares are essentially locked near the deal price. The primary trading consideration is the merger arbitrage spread and any regulatory/special meeting timing updates. Watch for shareholder vote date and FTC review. The standalone pipeline milestones (Phase 3 AD, EoE, asthma) are now AbbVie's story.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

APGE drug pipeline →

zumilokibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2 complete (positive); Phase 3 planned/initiating 2H 2026
Time to market
Phase 3 initiation guided to 2H 2026 with a company-flagged potential 2029 commercial launch in atopic dermatitis — roughly 3 years from now, assuming Phase 3 success and a standard filing/PDUFA path.
Next catalyst
None dated

What to watchFor APGE holders, the drug's upside is essentially monetized, the stock trades ~0.7% below the $135.11 all-cash offer, so the remaining question is simply whether the AbbVie deal closes in Q3 2026 (mean analyst target $130.53 vs. price ~$134 reflects the capped upside). For AbbVie investors, zumilokibart is a 2030s thesis: watch Phase 3 initiation in atopic dermatitis (guided 2H 2026), interim data from the head-to-head versus Dupixent (2H 2026), and the ~$0.14 FY2026 EPS dilution the deal carries, the Phase 3 readouts that could validate the ~$10.9B price tag are years away.

Price Chart

Loading chart...

Executive Summary

Apogee reported Q2 2026 financial results amid a transformational period: positive Phase 2 APEX Part B data for lead asset zumilokibart, a $1.3B non-dilutive financing collaboration with Blackstone Life Sciences, and the pending $10.9B acquisition by AbbVie at $135.11/share. Net loss widened to $85.9M from $66.1M YoY on higher R&D spend, but the acquisition agreement caps the stock near the deal price, rendering the earnings miss immaterial for current holders.

Key Facts

  • AbbVie to acquire Apogee for $135.11 per share in cash, total equity value ~$10.9 billion.
  • Blackstone Life Sciences provided up to $1.3B in non-dilutive capital to support zumilokibart Phase 3 and commercialization.
  • Phase 2 APEX Part B met all primary/secondary endpoints: 65.9% EASI-75 (41.9% placebo adjusted), supporting mid-dose for Phase 3 initiation in 2H 2026.
  • Expansion trials announced: ELEVATE Phase 2a in EoE (2H 2026) and ASPIRE Phase 2b registrational asthma trial (1H 2027).
  • Cash position $1.3B as of June 30, 2026, extending runway into 2029.
  • Q2 2026 net loss of $85.9M vs $66.1M YoY; R&D expenses $67.3M vs $55.7M YoY.
  • Revenue share liability of ~$99.2M recorded related to the Blackstone financing.
  • Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals.

Financial Impact

Acquisition valued at ~$10.9B total equity; Blackstone financing up to $1.3B non-dilutive capital; net loss of $85.9M in Q2 2026.

revenuenet_lossdilutioncash_positiondeal_value

Risk Factors

  • Transaction may fail to close due to regulatory hurdles or failure to obtain shareholder approval; break fee and litigation risk exist.
  • Zumilokibart Phase 3 results may not replicate Phase 2 efficacy; pipeline-expansion data (EoE, asthma) face clinical risk under AbbVie.
  • Expenses continuing to increase without revenue; business reliant on financing and acquisition proceeds.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
33% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-341239
Document: apge-20260810.htm0001193125-26-341239
Document: 0001193125-26-341239-index-headers.html0001193125-26-341239
Document: 0001193125-26-341239-index.html0001193125-26-341239
Document: 0001193125-26-341239.txt0001193125-26-341239
8-K Data (Synthetic)0001193125-26-341239

Track record

31 reports on APGE

Performance horizon

9 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 Viewing No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (9h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026